Miami, [March 2025] – Anemocyte is pleased to announce the opening of its new company in the United States, Anemocyte Inc., based in Miami, Florida.
This important strategic step marks the beginning of a significant expansion of Anemocyte’s pDNA and mRNA business in the North American market, after more than two decades of experience in the biotech field.
“Establishing a direct presence in the United States is a key milestone for our company,” said Marco Ferrari, CEO of Anemocyte. “In recent years, the demand for innovative solutions in the field of cell & gene therapy and nucleic acids has grown exponentially, and we want to be at the forefront of meeting this need. We have worked hard over the past months to make this opening possible, because we firmly believe that proximity to our partners and customers is essential to accelerate innovation and ensure the highest level of support. This new location is not only a gateway to the U.S. market, but also represents an opportunity to develop new strategic partnerships and strengthen our commitment to research and production of cutting-edge solutions. With our experience and technology, we are poised to bring significant added value to the biotech sector in the U.S.”
Together with the new opening , Anemocyte is pleased to announce the designation of a new Account Director, who will be based in Florida. The latter will be the contact person for U.S. customers and will enable the company to strengthen its presence in the territory, developing new business opportunities and consolidating relationships with key players in the industry.
Anemocyte’s U.S. expansion represents a fundamental step in the company’s global growth strategy, confirming its commitment to innovation and excellence in the development and delivery of high-quality, sustainable and effective solutions for the biotech industry.
For more information:
info@anemocyte.com
